The Peter Attia Drive cover image

The Peter Attia Drive

#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.

May 22, 2023
02:04:18

Podcast summary created with Snipd AI

Quick takeaways

  • Understanding the genetic basis of familial hypercholesterolemia is crucial for identifying high-risk individuals.
  • Comprehensive safety assessment in drug development can prevent unexpected adverse effects, as seen with past CETP inhibitors.

Deep dives

Challenges in Targeted Drug Development

Developing targeted drugs can be complex and challenging, as seen in the history of CTP inhibitors. Past experiences, like with torcetrapib, showed unexpected safety issues due to off-target effects. Understanding side effects thoroughly in early phases of drug development is crucial to prevent catastrophic failures in later stages. Torcetrapib, initially promising due to HDL cholesterol elevation, resulted in increased blood pressure and adverse outcomes in the outcome trial, highlighting the importance of comprehensive safety assessment in clinical trials.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode